https://orcid.org/0000-0001-9984-7196
References
- Cozzi, N. V., Sievert, M. K., Shulgin, A. T., Jacob, P., & Ruoho, A. E. (1999). Inhibition of plasma membrane monoamine transporters by β- ketoamphetamines. European Journal of Pharmacology, 381(1), 63–69. https://doi.org/10.1016/S0014-2999(99)00538-5
- Guirguis, A., Corkery, J. M., Stair, J. L., Kirton, S. B., Zloh, M., & Schifano, F. (2017). Intended and unintended use of cathinone mixtures. Human Psychopharmacology, 32(3), 1–17. https://doi.org/10.1002/hup.2598
- Leyrer-Jackson, J. M., Nagy, E. K., & Olive, M. F. (2019). Cognitive deficits and neurotoxicity induced by synthetic cathinones: Is there a role for neuroinflammation? Psychopharmacology, 236(3), 1079–1095. https://doi.org/10.1007/s00213-018-5067-5
- O’Connor, A. D., Padilla-Jones, A., Gerkin, R. D., & Levine, M. (2015). Prevalence of rhabdomyolysis in sympathomimetic toxicity: A comparison of stimulants. Journal of Medical Toxicology, 11(2), 195–200. https://doi.org/10.1007/s13181-014-0451-y
- Simmler, L. D., Buser, T. A., Donzelli, M., Schramm, Y., Dieu, L. H., Huwyler, J., Chaboz, S., Hoener, M. C., & Liechti, M. E. (2013). Pharmacological characterization of designer cathinones in vitro. British Journal of Pharmacology, 168(2), 458–470. https://doi.org/10.1111/j.1476-5381.2012.02145.x